AstraZeneca (NASDAQ:AZN) said on Monday that the late-stage trial for Enhertu, in combination with pertuzumab, showed ...

AstraZeneca's Alexion Pharmaceuticals was sued in Massachusetts federal court on Wednesday in a class action complaint ...

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line ...

AstraZeneca AZN will report its first-quarter 2025 earnings on April 29, before market open. The Zacks Consensus Estimate for ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...

With biosimilars to AstraZeneca’s blockbuster rare blood disease med Soliris recently available in the U.S., nonprofit health ...

Topline results from a planned interim analysis of the DESTINY-Breast09 phase 3 trial showed Enhertu in combination with pertuzumab ...

Plus: Comcast rolls out small-business assistance; Richie Neal takes Trump to task for tariff policies; Healey rolls out new ...

A unit of AstraZeneca Plc is facing a new antitrust suit claiming the company monopolized the market for a blood disorder ...

A twice-a-day pill for advanced breast cancer has been approved for use on the NHS. The life-extending drug, called ...